Q1 Earnings Forecast for PVLA Issued By HC Wainwright

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Palvella Therapeutics in a research note issued on Wednesday, April 1st. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.89) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $270.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.19) EPS and Q4 2026 earnings at ($1.30) EPS.

Several other equities research analysts also recently issued reports on PVLA. Truist Financial set a $210.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Chardan Capital boosted their target price on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the company a “buy” rating in a research report on Tuesday. Mizuho upped their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, BTIG Research lifted their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $198.07.

Palvella Therapeutics Trading Up 2.6%

Shares of NASDAQ PVLA opened at $123.46 on Thursday. The company has a market capitalization of $1.46 billion, a P/E ratio of -33.28 and a beta of -0.20. Palvella Therapeutics has a 12 month low of $18.23 and a 12 month high of $151.18. The stock has a 50 day moving average of $106.43 and a 200-day moving average of $92.07.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13).

Insider Buying and Selling

In related news, Director Elaine J. Heron acquired 2,400 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average price of $125.00 per share, with a total value of $300,000.00. Following the purchase, the director directly owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by corporate insiders.

Institutional Trading of Palvella Therapeutics

A number of hedge funds have recently made changes to their positions in PVLA. Federated Hermes Inc. bought a new position in Palvella Therapeutics in the 3rd quarter valued at approximately $21,255,000. Aspiriant LLC acquired a new position in Palvella Therapeutics in the 3rd quarter valued at approximately $367,000. Aberdeen Group plc bought a new position in shares of Palvella Therapeutics during the third quarter valued at $3,212,000. Frazier Life Sciences Management L.P. lifted its holdings in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after purchasing an additional 32,388 shares during the period. Finally, XTX Topco Ltd bought a new stake in shares of Palvella Therapeutics in the second quarter worth $399,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.